About this listing
FXOpen Official: Leading Forex Broker is a Telegram channel listed on TeleHub. View its description, category, member count, and Telegram join link.
TelehubJoin FXOpen for expert insights and trading updates! 🌍 Spreads from 0.0 pips on 700+ instruments.
FXOpen Official: Leading Forex Broker is a Telegram channel listed on TeleHub. View its description, category, member count, and Telegram join link.
Welcome to FXOpen, your gateway to premier Forex trading! With over **700 instruments** and spreads starting from **0.0 pips**, we're here to help you navigate the complex world of trading effortlessly. 💰 **Why Choose FXOpen?** - Regulated by FCA & CySEC, ensuring your peace of mind. - Exclusive market analysis & insights delivered straight to your feed! - Opportunities in more than **50 forex markets**, operating **24/5 hours** with deep liquidity. 📊 Our members enjoy rich resources such as: - Real-time analytics keeping you updated on crucial market shifts. - A vibrant chat group at @fxo_chat for discussions ranging from strategies to latest news! 🔗 Don’t miss out! Keep ahead with our updates regarding economic reports and central bank decisions influencing your trades. For further information about our services, feel free to visit [our linktree](https://linktr.ee/fxopen). Forex can involve significant risk; make sure you're aware that CFDs are complex financial products that could lead to rapid capital losses. Join us today and enhance your trading journey with FXOpen!
Loading recent Telegram analytics…
TeleHub helps users discover Telegram communities, but users should review each community before joining. Report misleading, unsafe, or inappropriate listings.
Report a listingClick the join button to open FXOpen Official: Leading Forex Broker on Telegram.
No, FXOpen Official: Leading Forex Broker is not marked as NSFW. Users should still review the community before joining.
FXOpen Official: Leading Forex Broker is listed under Forex Trading, Market Analysis, Financial Services, Investment, Analytics on TeleHub.
Statistics updated October 17, 2026
Post frequency is estimated from the latest 30 stored public posts and may undercount activity.
#USDJPY #USDCAD #forextrading #tradingtips #MarketNews USD/CAD USD/CAD has recovered from its recent lows and is testing the 1.3895–1.3940 resistance area, despite support for the Canadian dollar from elevated oil prices. A firm move above 1.3940, followed by the level turning into support, could pave the way for a rise towards 1.4000–1.4030. A failed attempt to establish itself above the current resistance area, by contrast, could trigger a renewed decline towards the 1.3760 support level. Key events for USD/CAD: ▪️today at 15:30 (GMT+3): Canadian building permits; ▪️today at 17:30 (GMT+3): US crude oil inventories; ▪️today at 18:30 (GMT+3): Federal Reserve Bank of Atlanta GDPNow indicator. Overall, USD/JPY and USD/CAD remain in consolidation ahead of the key Fed decision. As a 25-basis-point rate hike is already largely priced in, the dollar’s subsequent reaction will depend primarily on the central bank’s projections and rhetoric. Signals pointing to further tightening could support gains in both pairs, while a more cautious Fed stance could put renewed pressure on the US currency. Trade over 50 forex markets 24 hours a day with FXOpen. Take advantage of low commissions, deep liquidity, and spreads from 0.0 pips*. Learn more about trading commodity CFDs with FXOpen. *Additional fees may apply. CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. You should consider whether you understand how CFDs work, and whether you can afford to take the high risk of losing your money. You can find the full disclaimer here: www.fxopen.com This article represents the opinion of the Companies operating under the FXOpen brand only. It is not to be construed as an offer, solicitation, or recommendation with respect to products and services provided by the Companies operating under the FXOpen brand, nor is it to be considered financial advice.
#USDJPY #USDCAD #forextrading #tradingtips #marketanalysis #MarketNews USD/JPY and USD/CAD Await Key Fed Decision The US dollar is consolidating against the yen and Canadian dollar ahead of the key event of the week — the Federal Reserve meeting. The Fed is widely expected to raise its policy rate by 25 basis points to a range of 3.75–4.00%. As this move is already largely priced in, attention will focus on the updated economic projections, dot plot and press conference. Investors will assess whether the September rate hike marks the beginning of a new phase of monetary tightening or whether the central bank will prefer to adopt a wait-and-see approach. Expectations of a more hawkish Fed are supported by persistent inflationary pressures, recent employment data and rising oil prices. US retail sales data will provide an additional reference point ahead of the meeting. Strong figures could provide further support for the dollar, although the market reaction is likely to remain limited ahead of the Fed decision. USD/JPY The decline in USD/JPY over the past two weeks has slowed around the key support area of 152.90–153.20. At the start of the week, the price tested this area several times, while buyers managed to establish a foothold above the psychological 155.00 level yesterday. Hawkish Fed rhetoric could support a corrective rise in USD/JPY towards 156.20–157.00. More cautious signals regarding further policy tightening, by contrast, could put renewed pressure on the dollar and lead to another test of the 152.90–153.20 area. Key events for USD/JPY: ▪️today at 15:30 (GMT+3): US core retail sales; ▪️today at 21:00 (GMT+3): US Federal Reserve interest rate decision; ▪️today at 21:30 (GMT+3): Federal Open Market Committee press conference.
#stockmarket #stocktrading #marketanalysis #MarketNews UnitedHealth: Fundamentals Are Healing, Now the Chart Must Agree UnitedHealth finds itself in a genuinely split narrative right now, trading near $388, down about 15.9% from its 52-week high, even as the fundamental picture keeps improving. Q2 earnings beat expectations, with revenue of $112.03 billion, and the company followed through with a significant policy shift: lifting prior-authorization requirements on roughly 1,700 diagnostic codes starting October 1, a move that could meaningfully ease administrative friction with providers and support margins going forward. Wall Street's conviction has only grown stronger as a result. Wells Fargo and Bernstein both reaffirmed Buy ratings this month, with price targets near $526 and $512 respectively, while the broader consensus, a Moderate Buy across 27 analysts, points to an average target of $456.56, implying roughly 17% upside from current levels. The stock has nonetheless struggled to find sustained momentum, weighed down by lingering concerns over Medicare Advantage margin recovery and, more recently, the shock of losing a senior executive, an event that has triggered internal restructuring and closer scrutiny of governance and security practices. The result: a company delivering genuinely solid operational improvement, but one whose stock price has yet to fully reflect it. Technical Analysis of UnitedHealth As the UNH daily chart shows, the stock remains in a broader downtrend from July's highs near $459.51, currently testing a critical confluence near $374–383, where the 0.382 Fibonacci retracement and the 200-period EMA all converge. Adding intrigue to the setup, the RSI is forming a bullish divergence, printing higher highs even as price carved a fresh low in recent sessions. Bullish Scenario Should buyers break above this EMA-Fibonacci confluence, the divergence would gain real technical credibility, opening the path towards a retest of the broader downtrend structure and potentially challenging the $450–$460 area, where the stock has its recent high in July. Bearish Scenario Conversely, a rejection at this confluence would keep sellers in control, invalidating the divergence and exposing the 0.5 retracement near $357.46, with a deeper slide risking a retest of the 0.618 level around $333.37, the support zone that held throughout last autumn and winter. With price testing a stubborn multi-factor confluence while the RSI quietly hints at fading downside momentum, UnitedHealth's next move looks set to determine whether the fundamental recovery story finally gains technical confirmation, or whether the broader downtrend still has room to run. Trade global index CFDs with zero commission and tight spreads*. Learn more about trading index CFDs with FXOpen. *Additional fees may apply. CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. You should consider whether you understand how CFDs work, and whether you can afford to take the high risk of losing your money. You can find the full disclaimer here: www.fxopen.com This article represents the opinion of the Companies operating under the FXOpen brand only. It is not to be construed as an offer, solicitation, or recommendation with respect to products and services provided by the Companies operating under the FXOpen brand, nor is it to be considered financial advice.